In the same way, Hagin et al. observed a positive response, but at lower levels than healthy controls in a cohort of 13 CVID patients treated with immunoglobulins, measuring the SARS-CoV-2 anti-protein S antibody response 2 weeks after the second dose of the Pfizer-BioNTech vaccine [9]. This evidence concerns the gene PROS1 and common variable immunodeficiency.